News

Understanding Schouw & Co.'s Recent Share Buy-Back Initiative

Understanding Schouw & Co.'s Recent Share Buy-Back Initiative

Insights into Schouw & Co.'s Share Buy-Back Programme

In an effort to manage their capital efficiently and return value to shareholders, Schouw & Co. has initiated a share buy-back programme. This move allows the company to buy back its own shares, a strategy designed to improve shareholder returns and enhance the overall financial health of the organization.

Programme Details and Structure

Launched on 5 May 2025, Schouw & Co. plans to repurchase shares for an amount not exceeding DKK 120 million. The programme is set to run until 31 December 2025. Such a commitment reflects the confidence the management has in the growth trajectory and profitability of the company.

The structuring of the buy-back is done in compliance with the Regulation (EU) No. 596/2014, which establishes the guidelines against market abuse, ensuring transparency and integrity in the financial practices of Schouw & Co.

Recent Transactions and Progress

As part of the ongoing share buy-back programme, significant transactions have already taken place. Up until now, Schouw & Co. has been actively acquiring shares. By 25 July 2025, the company had repurchased a total of 82,300 shares at an average price of DKK 592.92 each, leading to a total expenditure of approximately DKK 48.8 million.

Continuing this trend, on various trading days from the end of July to the beginning of August, the company has added more shares to its holdings. For instance, on 28 July, 1,000 shares were purchased at an average price of DKK 627.61, totaling DKK 627,610. Each transaction not only illustrates the company's commitment to capital management but also reflects strategic timing in the financial markets.

Summary of Transactions

Below is a summary of the recent trading activities:

  • 28 July 2025: Purchased 1,000 shares at DKK 627.61
  • 29 July 2025: Purchased 1,000 shares at DKK 624.94
  • 30 July 2025: Purchased 1,000 shares at DKK 623.15
  • 31 July 2025: Purchased 1,000 shares at DKK 619.65
  • 1 August 2025: Purchased 1,200 shares at DKK 612.71

After the completion of these transactions from 28 July to 1 August, Schouw & Co. had accumulated a total of 87,500 shares secured through this buy-back effort.

Strategic Implications of the Buy-Back

The rationale behind such buy-back programmes often includes the aim to consolidate earnings per share (EPS) by reducing the share count, thus providing tangible benefits to remaining shareholders. Companies can become more attractive to investors looking for growth potential when they demonstrate proactive measures to optimize their capital structure. Furthermore, holding treasury shares contributes to maintaining a healthy balance sheet and financial flexibility.

Currently, Schouw & Co. has a total of 2,129,493 treasury shares, amounting to approximately 8.52% of the total share capital of 25 million shares.

Company Contact Information

For inquiries or further information regarding the buy-back programme, please reach out to:
Aktieselskabet Schouw & Co.
Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President
Telephone: +45 86 11 22 22

Frequently Asked Questions

What is the purpose of the share buy-back programme?

The purpose is to manage capital effectively and return value to shareholders by purchasing the company's own shares.

How much does Schouw & Co. plan to spend on the buy-back?

The company intends to spend up to DKK 120 million on the share buy-back programme.

What guidelines does the buy-back follow?

The buy-back programme is conducted in accordance with Regulation (EU) No. 596/2014, which addresses market abuse.

How many shares has Schouw & Co. repurchased so far?

As of 1 August 2025, the company has repurchased a total of 87,500 shares.

Who can I contact for more information about the buy-back?

For further details, you can contact Jørgen Dencker Wisborg or Jens Bjerg Sørensen at the company.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohat University Teams Up with MindHYVE.ai for AI Learning

Updated Category News Views 283

Kohat University Partners with MindHYVE.ai to Innovate Education In a significant advancement for higher education in the region, Kohat University of Science & Technology (KUST) has established a strategic partnership with MindHYVE.ai™. This collaboration aims to introduce ArthurAI™, an advanced learning platform that utilizes agentic AI technology, into its academic...

Continue Reading
Lulus Enhances Market Reach Through Innovative Collaborations

Updated Category News Views 336

Expanding Market Reach Through Strategic Collaborations LOS ANGELES, A prominent player in the fashion industry, Lulus is taking significant steps to enhance its market presence and reach customers in new and exciting ways. By initiating collaborations with various platforms, Lulus is keen on tapping into emerging retail channels and broadening its accessibility....

Continue Reading
Explore Top Gardening Trends for Fall by Calloway's Nursery

Updated Category News Views 172

Embracing Fall Gardening Trends with Calloway's Nursery As the seasons change, so does the opportunity to refresh our gardens and outdoor spaces. Calloway's Nursery is here to help you embrace the beauty of fall gardening. The nursery’s offerings are tailored to inspire Texans to create vibrant and inviting spaces. Fantastic Fall Container Gardens Container gardens are...

Continue Reading
happyactually Strengthens Leadership with Dr. Andia Shahzadi

Updated Category News Views 119

happyactually Appoints Dr. Andia Shahzadi as Chief Medical Officer happyactually, an innovative wellbeing technology firm, proudly announces the elevation of Dr. Andia Shahzadi to the position of Chief Medical Officer and Founding Member of the team. This change marks a significant step in the company's aim to empower life-conscious individuals through scientifically...

Continue Reading
Surrozen to Showcase Innovations at Investor Conference Soon

Updated Category News Views 76

Surrozen Announces Presentation at Healthcare Investor Conference Recently, Surrozen, Inc. (Nasdaq: SRZN), a pioneering biotechnology company based in South San Francisco, revealed that its management team will be presenting at an upcoming healthcare investor conference. The company specializes in targeted therapeutics that focus on selectively modulating the Wnt pathway,...

Continue Reading